PHARMACY POLICY STATEMENT
North Carolina Marketplace

DRUG NAME	Pegfilgrastim (Fulphila, Neulasta, Nyvepria, Udenyca CBM2797 CxtMens(o)-5.4
BILLING CODE	See below
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Home/Office/Outpatient
STATUS	Prior Authorization Required

Pegfilgrastim is a colony stimulating factor with a prolonged duration of effect that boosts the production and activation of neutrophils in individuals who are immunosuppressed as a result of myelosuppressive chemotherapy or exposure to myelosuppressive does of radiation.

It was initially approved by the FDA in 2022 as Neulasta. Since then, the FDA has approved the following biosimilars: Udenyca (2018), Fulphila (2018), Ziextenzo (2019), and Nyvepria (2020). All of the biosimilar pegfilgrastim products share the indication for prevention of febrile neutropenia due to myelosuppressive

Dosage allowed/Quantity limit: Up to 6 mg per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy (2 units per 28 days).

CareSource considers pegfilgrastim not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
5/27/2022	New policy for pegfilgrastim products created outlining preferred/non-preferred biosimilar products. NantHealth link added for prevention of febrile neutropenia.

References:

1. Nyvepria [package insert]. New York, NY: Pfizer Inc; 2020. Accessed May 27, 2022.
2. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc; 2019 Accessed May 27, 2022.
3. NCCN Guidelines for Hematopoietic Growth Factors, Version 1.2022, Pages MGF-1 through MGF-D.
4. National Comprehensive Cancer Network. (2022). NCCN Drugs & Biologics Compendium™. Pegfilgrastim. Retrieved May 27, 2022. from the National Comprehensive Cancer Network.
5. Neulasta. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed May 27, 2022.
6.